Portfolio Sync Solutions
Streamline your investment strategy with our portfolio synchronization tools. Seamlessly manage and track your holdings across platforms for enhanced
GET STARTEDMarker Therapeutics, Inc. Analyst EPS Estimates
| Quarter | Number of Estimates | Low Estimate | High Estimate | Average Estimate |
|---|---|---|---|---|
| Q1 2024 | 1 | -$0.43 | -$0.43 | -$0.43 |
| Q2 2024 | 1 | -$0.39 | -$0.39 | -$0.39 |
| Q3 2024 | 1 | -$0.28 | -$0.28 | -$0.28 |
| Q1 2025 | 1 | -$0.32 | -$0.32 | -$0.32 |
| Q2 2025 | 1 | -$0.48 | -$0.48 | -$0.48 |
| Q3 2025 | 1 | -$0.62 | -$0.62 | -$0.62 |
| Q4 2025 | 1 | -$0.77 | -$0.77 | -$0.77 |
Marker Therapeutics, Inc. Earnings Date And Information
Marker Therapeutics, Inc. last posted its earnings results on Wednesday, August 14th, 2024. The company reported $-0.25 earnings per share for the quarter, topping analysts' consensus estimates of $-0.43 by $0.18. The company had revenue of 1.93 M for the quarter and had revenue of 3.31 M for the year. Marker Therapeutics, Inc. has generated $-2 earnings per share over the last year ($-1.93 diluted earnings per share) and currently has a price-to-earnings ratio of -3.23. Marker Therapeutics, Inc. has not formally confirmed its next earnings publication date, but the company's estimated earnings date is Monday, March 24th, 2025 based on prior year's report dates.
Marker Therapeutics, Inc. Earnings History by Quarter
| Date | Quarter | Consensus Estimate | Reported EPS | Beat/Miss | Revenue Estimate | Actual Revenue |
|---|---|---|---|---|---|---|
| 11/14/2024 | Q3 2024 | -$0.26 | $1.00 M | $1.93 M | ||
| 08/14/2024 | Q2 2024 | -$0.43 | -$0.25 | 0.18 | $1.17 M | $1.17 M |
| 05/15/2024 | Q1 2024 | -$0.25 | -$0.27 | -0.02 | $1.24 M | |
| 03/25/2024 | Q4 2023 | -$1.00 | -$0.31 | 0.69 | $1.06 M | |
| 11/09/2023 | Q3 2023 | -$0.34 | $257,606 | |||
| 08/14/2023 | Q2 2023 | -$0.71 | $762,658 | |||
| 05/15/2023 | Q1 2023 | -$0.56 | $3.50 M | |||
| 03/22/2023 | Q4 2022 | -$1.00 | -$0.48 | 0.52 | $6.05 M | |
| 11/10/2022 | Q3 2022 | -$1.30 | -$0.83 | 0.47 | $400,000 | $2.95 M |
| 08/11/2022 | Q2 2022 | -$1.30 | -$1.10 | 0.2 | $2.50 M | $791,000 |
| 05/12/2022 | Q1 2022 | -$1.30 | -$1.19 | 0.11 | $964,000 | |
| 03/17/2022 | Q4 2021 | -$1.20 | -$1.19 | 0.01 | $1.24 M | |
| 11/10/2021 | Q3 2021 | -$1.30 | -$1.50 | -0.2 | $0 | |
| 08/10/2021 | Q2 2021 | -$1.20 | -$1.31 | -0.11 | $0 | |
| 05/12/2021 | Q1 2021 | -$1.60 | -$1.55 | 0.05 | $0 | |
| 03/09/2021 | Q4 2020 | -$1.60 | -$1.75 | -0.15 | $215 | |
| 11/09/2020 | Q3 2020 | -$1.50 | -$1.57 | -0.07 | $0 | |
| 08/10/2020 | Q2 2020 | -$1.40 | -$1.36 | 0.04 | $466,785 | |
| 05/11/2020 | Q1 2020 | -$1.30 | -$1.41 | -0.11 | $0 | |
| 03/12/2020 | Q4 2019 | -$1.30 | -$1.11 | 0.19 | $213,194 |
Marker Therapeutics, Inc. Earnings: FAQ's
When is Marker Therapeutics, Inc.'s earnings date?
Marker Therapeutics, Inc. has not confirmed its next earnings publication date, but the company's estimated earnings date is Monday, March 24th, 2025 based off last year's report dates.
Did Marker Therapeutics, Inc. beat their earnings estimates last
quarter?
In the previous quarter, Marker Therapeutics, Inc. (:MRKR) reported $-0.25 earnings per share (EPS) to beat the analysts' consensus estimate of $-0.43 by $0.18.
How can I listen to Marker Therapeutics, Inc.'s earnings conference
call?
The conference call for Marker Therapeutics, Inc.'s latest earnings report can be listened to online.
How can I read Marker Therapeutics, Inc.'s conference call transcript?
The conference call transcript for Marker Therapeutics, Inc.'s latest earnings report can be read online.
How much revenue does Marker Therapeutics, Inc. generate each year?
Marker Therapeutics, Inc. (:MRKR) has a recorded annual revenue of $3.31 M.
How much profit does Marker Therapeutics, Inc. generate each year?
Marker Therapeutics, Inc. (:MRKR) has a recorded net income of $3.31 M. Marker Therapeutics, Inc. has generated $-1.93 earnings per share over the last four quarters.
What is Marker Therapeutics, Inc.'s price-to-earnings ratio?
Marker Therapeutics, Inc. (:MRKR) has a price-to-earnings ratio of -3.23 and price/earnings-to-growth ratio is -0.47.